iZafe Group AB Series B (IZAFE-B) - Total Assets
Based on the latest financial reports, iZafe Group AB Series B (IZAFE-B) holds total assets worth Skr40.20 Million SEK (≈ $4.33 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See iZafe Group AB Series B shareholders equity for net asset value and shareholders' equity analysis.
iZafe Group AB Series B - Total Assets Trend (2010–2024)
This chart illustrates how iZafe Group AB Series B's total assets have evolved over time, based on quarterly financial data.
iZafe Group AB Series B - Asset Composition Analysis
Current Asset Composition (December 2024)
iZafe Group AB Series B's total assets of Skr40.20 Million consist of 27.9% current assets and 72.2% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr2.15 Million | 8.9% |
| Accounts Receivable | Skr1.08 Million | 4.5% |
| Inventory | Skr2.97 Million | 12.2% |
| Property, Plant & Equipment | Skr1.05 Million | 4.3% |
| Intangible Assets | Skr16.43 Million | 67.8% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how iZafe Group AB Series B's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IZAFE-B stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: iZafe Group AB Series B's current assets represent 27.9% of total assets in 2024, an increase from 4.8% in 2010.
- Cash Position: Cash and equivalents constituted 8.9% of total assets in 2024, up from 1.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 67.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 67.8% of total assets.
iZafe Group AB Series B Competitors by Total Assets
Key competitors of iZafe Group AB Series B based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
iRay Technology Co Ltd
SHG:688301
|
China | CN¥11.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$272.48 Million |
|
Jiangsu Nanfang Medical
SHG:603880
|
China | CN¥993.46 Million |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.32 Billion |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
iZafe Group AB Series B - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.29 | 0.82 | 1.96 |
| Quick Ratio | 0.91 | 0.44 | 1.55 |
| Cash Ratio | 0.60 | 0.30 | 0.00 |
| Working Capital | Skr2.33 Million | Skr-1.98 Million | Skr5.42 Million |
iZafe Group AB Series B - Advanced Valuation Insights
This section examines the relationship between iZafe Group AB Series B's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.86 |
| Latest Market Cap to Assets Ratio | 0.61 |
| Asset Growth Rate (YoY) | -30.0% |
| Total Assets | Skr24.23 Million |
| Market Capitalization | $14.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values iZafe Group AB Series B's assets below their book value (0.61x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: iZafe Group AB Series B's assets decreased by 30.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for iZafe Group AB Series B (2010–2024)
The table below shows the annual total assets of iZafe Group AB Series B from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr24.23 Million ≈ $2.61 Million |
-30.00% |
| 2023-12-31 | Skr34.61 Million ≈ $3.73 Million |
-31.73% |
| 2022-12-31 | Skr50.70 Million ≈ $5.46 Million |
+4.69% |
| 2021-12-31 | Skr48.43 Million ≈ $5.21 Million |
+38.05% |
| 2020-12-31 | Skr35.08 Million ≈ $3.78 Million |
-51.11% |
| 2019-12-31 | Skr71.75 Million ≈ $7.72 Million |
+64.64% |
| 2018-12-31 | Skr43.58 Million ≈ $4.69 Million |
+217.78% |
| 2017-12-31 | Skr13.71 Million ≈ $1.48 Million |
+69.47% |
| 2016-12-31 | Skr8.09 Million ≈ $870.88K |
-34.85% |
| 2015-12-31 | Skr12.42 Million ≈ $1.34 Million |
-17.76% |
| 2014-12-31 | Skr15.10 Million ≈ $1.63 Million |
-11.70% |
| 2013-12-31 | Skr17.11 Million ≈ $1.84 Million |
-29.02% |
| 2012-12-31 | Skr24.10 Million ≈ $2.59 Million |
+577.71% |
| 2011-12-31 | Skr3.56 Million ≈ $382.71K |
-26.87% |
| 2010-12-31 | Skr4.86 Million ≈ $523.30K |
-- |
About iZafe Group AB Series B
iZafe Group AB (publ), a medical technology company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated medication dispenser that handles medication pouches, smart pillboxes, facilitates and enables independent medication, and reminds and alerts in the scheduled doses. It also o… Read more